HOLOGIC DIGITAL MAMMOGRAPHY SYSTEM IS FIRST TO RECEIVE EUREF “MAMMOGRAPHIC TYPE TEST” CERTIFICATION
Certification ensures users that the Hologic Selenia system meets or exceeds rigorous European image quality and dose standards
BEDFORD, Mass. (June 22, 2010) /PRNewswire/ — Hologic, Inc. (Hologic or the Company) (NASDAQ: HOLX), a leading developer, manufacturer and supplier of premium diagnostics products, medical imaging systems and surgical products dedicated to serving...
OvaGene Oncology Opens New Innovative Gynecologic Cancer Laboratory and Research Facility
IRVINE, Calif., June 22 /PRNewswire/ -- OvaGene Oncology Inc., a biotechnology company specializing in the development and commercialization of personalized DNA-based diagnostics for gynecologic cancer, announced today the opening of its new clinical and research laboratory in Irvine, California. This state-of-the-art facility will serve as the central headquarters for operations, research, and...
Inovio Pharmaceuticals’ Optimized DNA Vaccine Demonstrates Significant Advantages in Non-Human Primates Compared to Leading Viral Vector Based Vaccine
Enhanced Potency of SynCon™ DNA Vaccines Delivered Using Electroporation Highlighted in Molecular Therapy
BLUE BELL, Pa.--(BUSINESS WIRE)--Inovio Pharmaceuticals, Inc. (NYSE Amex: INO), a leader in the development of therapeutic and preventive vaccines against...
Merck Sharp & Dohme Limited ("MSD") announced the results from a new trial comparing an anti-emetic regimen containing a single IV dose of fosaprepitant dimeglumine to one with three days of oral aprepitant.
The study found that the anti-emetic regimen of fosaprepitant dimeglumine administered as a single intravenous (IV) 150mg dose on Day 1 in combination with a 5-HT3 antagonist, and dexamethasone administered over 4 days, is non-inferior...
ROCHESTER, N.Y., June 22, 2010 (GLOBE NEWSWIRE) -- NaturalNano, Inc. (Pink Sheets:NNAN) (Frankfurt:N3N) announced today that Dr. Michael King, a researcher at Cornell University, has published a new study demonstrating how NaturalNano nanotubes can improve targeting of circulating tumor cells (CTC's). These nanotubes, when added to the surface where cancer cells are attracted, enhance the natural rolling mechanism that Dr. King believes will allow them to be exposed to specific drugs or other therapeutic...
